Hydroxychloroquine protects the annexinA5 anticoagulant shield from disruption by antiphospholipid antibodies: Evidence for a novel effect for an old antimalarial drug

Blood

Volumn 115, Issue 11, 2010, Pages 2292-2299

  Rand, Jacob H ^a   Wu, Xiao Xuan ^a   Quinn, Anthony S ^b   Ashton, Anthony W ^a   Chen, Pojen P ^c   Hathcock, James J ^d   Andree, Harry A M ^d   Taatjes, Douglas J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; LIPOCORTIN 5; PHOSPHOLIPID ANTIBODY; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT;

ANTICOAGULATION; ARTICLE; ATOMIC FORCE MICROSCOPY; BLOOD CLOTTING TIME; BLOOD SAMPLING; CELL LINE; CELL SURFACE; DRUG EFFECT; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN BINDING; TROPHOBLAST; UMBILICAL VEIN; ANTIPHOSPHOLIPID SYNDROME; BLOOD; BLOOD CLOTTING; CELL CULTURE; CRYSTALLIZATION; IMMUNOLOGY; LIPID BILAYER; METABOLISM; ULTRASTRUCTURE;

ANNEXIN A5; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIMALARIALS; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; CELLS, CULTURED; CRYSTALLIZATION; HUMANS; HYDROXYCHLOROQUINE; LIPID BILAYERS; MICROSCOPY, ATOMIC FORCE; PROTEIN BINDING;

EID: 77950435764     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-04-213520     Document Type: Article

References (50)

1. Ginsberg JS, Wells PS, Brill Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;86:3685-3691.
2. Out HJ, Bruinse HW, Christiaens GC, et al. Prevalence of antiphospholipid antibodies in patients with fetal loss. Ann Rheum Dis. 1991;50:553-557.
3. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. J Am Med Assoc. 2006;295:1050-1057. (Pubitemid 43313721)
4. Rand JH, Wu XX, Quinn AS, Taatjes DJ. Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. Lupus. 2008;17:922-930.
5. Andree HAM, Stuart MC, Hermens WT, et al. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem. 1992;267:17907-17912.
6. Tait JF, Sakata M, McMullen BA, et al. Placental anticoagulant proteins: isolation and comparative characterization for members of the lipocortin family. Biochemistry. 1988;27:6268-6276.
7. Reviakine I, Bergsma-Schutter W, Mazeres-Dubut C, Govorukhina N, Brisson A. Surface topography of the p3 and p6 annexin V crystal forms determined by atomic force microscopy. J Struct Biol. 2000;131:234-239.
8. Rand JH, Wu XX, Andree HAM, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood. 1998;92:1652-1660.
9. Hanly JG, Smith SA. Anti-β2-glycoprotein I (GPI) autoantibodies, annexin V binding and the antiphospholipid syndrome. Clin Exp Immunol. 2000;120:537-543.
10. Gaspersic N, Ambrozic A, Bozic B, et al. Annexin A5 binding to giant phospholipid vesicles is differentially affected by anti-β2-glycoprotein I and anti-annexin A5 antibodies. Rheumatology. 2007;46:81-86.
11. Tomer A. Antiphospholipid antibody syndrome: rapid, sensitive, and specific flow cytometric assay for determination of anti-platelet phospholipid autoantibodies. J Lab Clin Med. 2002;139:147-154. (Pubitemid 34286951)
12. Rand JH, Wu XX, Quinn AS, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol. 2003;163:1193-1200.
13. Rand JH, Wu XX, Guller S, et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol. 1994;171:1566-1572.
14. Rand JH, Wu XX, Andree HA, et al. Pregnancy loss in the antiphospholipid-antibody syndrome: a possible thrombogenic mechanism. N Engl J Med. 1997;337:154-160.
15. Vogt E, Ng AK, Rote NS. Antiphosphatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation. Am J Obstet Gynecol. 1997;177:964-972. (Pubitemid 27516075)
16. Cederholm A, Svenungsson E, Jensen-Urstad K, et al. Decreased binding of annexin V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol. 2005;25:198-203. (Pubitemid 40054276)
17. de Laat B, Wu XX, van Lummel M, et al. Correlation between antiphospholipid antibodies that recognize domain I of β2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood. 2007;109:1490-1494.
18. Galli M, Luciani D, Bertolini G, Barbui T. Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003;102:2717-2723.
19. Tomer A, Bar-Lev S, Fleisher S, et al. Antiphospholipid antibody syndrome: the flow cytometric annexin A5 competition assay as a diagnostic tool. Br J Haematol. 2007;139:113-120. (Pubitemid 47389926)
20. Rand JH, Wu XX, Lapinski R, et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood. 2004;104:2783-2790. (Pubitemid 39434962)
21. Wu XX, Pierangeli SS, Rand JH. Resistance to annexin A5 binding and anticoagulant activity in plasmas from patients with the antiphospholipid syndrome but not with syphilis. J Thromb Haemost. 2006;4:271-273.
22. Rand JH, Arslan AA, Wu XX, et al. Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol. 2006;194:182-188. (Pubitemid 43017794)
23. Rothfield N. Efficacy of antimalarials in systemic lupus erythematosus. Am J Med. 1988;85:53-56.
24. Tsakonas E, Joseph L, Esdaile JM, et al. A longterm study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus: the Canadian Hydroxychloroquine Study Group. Lupus. 1998;7:80-85.
25. Molad Y, Gorshtein A, Wysenbeek AJ, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus: prospective long-term study of an Israeli cohort. Lupus. 2002;11:356-361. (Pubitemid 34760633)
26. Fessler BJ, Alarcon GS, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52:1473-1480.
27. Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum. 1987;30:1435-1436.
28. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol. 1996;25:191-193. (Pubitemid 26273848)
29. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multiethnic cohort. Ann Rheum Dis. 2009;68:238-241.
30. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61:29-36.
31. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology. 2002;41:924-929.
32. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577-583. (Pubitemid 44661744)
33. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2009.
34. Edwards MH, Pierangeli S, Liu X, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1997;96:4380-4384. (Pubitemid 28007469)
35. Espinola RG, Pierangeli SS, Ghara AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost. 2002;87:518-522.
36. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-β2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112:1687-1695.
37. Zhu M, Olee T, Le DT, et al. Characterization of IgG monoclonal anti-cardiolipin/anti-β2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies. Br J Haematol. 1999;105:102-109. (Pubitemid 29197150)
38. Pierangeli SS, Liu X, Espinola R, et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost. 2000;84:388-395.
39. Ashton AW, Yokota R, John G, et al. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A2. J Biol Chem. 1999;274:35562-35570. (Pubitemid 129512852)
40. Pengo V, Tripodi A, Reber G, et al. Official communication of the scientific and standardization committee on lupus anticoagulant/ phospholipiddependent antibodies: update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7:1737-1740.
41. Gamsjaeger R, Johs A, Gries A, et al. Membrane binding of β2-glycoprotein I can be described by a two-state reaction model: an atomic force microscopy and surface plasmon resonance study. Biochem J. 2005;389:665-673. (Pubitemid 41117326)
42. Rand JH, Wu XX, Guller S, et al. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol. 1997;177:918-923. (Pubitemid 27516067)
43. Krikun G, Lockwood CJ, Wu XX, et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta. 1994;15:601-612. (Pubitemid 24295067)
44. Wang X, Campos B, Kaetzel MA, Dedman JR. Annexin V is critical in the maintenance of murine placental integrity. Am J Obstet Gynecol. 1999;180:1008-1016. (Pubitemid 29200569)
45. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54:3640-3647.
46. Hoekenga MT. The treatment of acute malaria with single oral doses of amodiaquin, chloroquine, hydroxychloroquine and pyrimethamine. Am J Trop Med Hyg. 1954;3:833-838.
47. Tye MJ, White H, Appel B, Ansell HB. Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine and chloroquine. N Engl J Med. 1959;260:63-66.
48. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66:821-824. (Pubitemid 46846706)
49. de Laat B, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodies: from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol. 2008;4:192-199.
50. Erkan D, Lockshin MD. New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol. 2009;5:160-170.